Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol 2023; 44(01): 110-118
DOI: 10.1055/s-0042-1759519
Review Article

Imaging Recommendations for Diagnosis, Staging, and Management of Uterine Cancer

Smita Manchanda
1   Department of Radiodiagnosis and Interventional Radiology, All India Institute of Medical Sciences, New Delhi, India
,
Anthoni Bala Subashree
1   Department of Radiodiagnosis and Interventional Radiology, All India Institute of Medical Sciences, New Delhi, India
,
Rupa Renganathan
2   Department of Diagnostic and Interventional Radiology, Kovai Medical Center and Hospitals, Coimbatore, Tamil Nadu, India
,
Palak Bhavesh Popat
3   Breast Imaging and Interventions, Department of Radiology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Ekta Dhamija
4   Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, India
,
Seema Singhal
5   Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India
,
Neerja Bhatla
5   Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Uterine cancers are classified into cancers of the corpus uteri (uterine carcinomas and carcinosarcoma) and corpus uteri (sarcomas) by the AJCC staging system (eighth edition). Endometrial carcinoma is the most common amongst these with prolonged estrogen exposure being a well-known risk factor. The FIGO staging system for endometrial carcinoma is primarily surgical and includes total hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy. Imaging is useful in the preoperative evaluation of tumor stage, especially assessment of myometrial invasion and cervical stromal extension. Dynamic contrast enhanced MRI with DWI has a high staging accuracy and is the preferred imaging modality for primary evaluation with contrast-enhanced CT abdomen being indicated for recurrent disease. PET/CT is considered superior in evaluation of lymph nodes and extra pelvic metastases.

Keywords

dynamic contrast-enhanced MRI - endometrial neoplasms - gynecology and obstetrics - leiomyosarcoma - magnetic resonance imaging - medical oncology - positron emission tomography computed tomography - radiology


Publication History

Article published online:
24 January 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Female Genital Tumours. WHO Classification of Tumors, 5th ed. Vol. 4. Lyon, France. International Agency for Research on Cancer; 2020
    Google Scholar
  • 2 Abu-Rustum NR, Yashar CM, Bradley K. et al. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. J Natl Compr Canc Netw 2021; 19 (08) 888-895
    CrossrefPubMedGoogle Scholar
  • 3 Amin MB, Greene FL, Edge SB. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: 93-99
    CrossrefPubMedGoogle Scholar
  • 4 ICMR Indian Council of Medical Research Consensus document for management of uterine cancer 2019. Accessed on February 20, 2022, at: https://main.icmr.nic.in/sites/default/files/guidelines/Uterine_Cancer.pdf
  • 5 McMeekin DS, Yashar C, Campos SM, Zaino RJ. Corpus: epithelial tumors. In: Barakat RR, Berchuk A, Markman M, Randall M, eds. Principles and Practice of Gynecologic Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins(LWW); 2013: 661-714
    Google Scholar
  • 6 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    CrossrefPubMedGoogle Scholar
  • 7 Mathur P, Sathishkumar K, Chaturvedi M. et al; ICMR-NCDIR-NCRP Investigator Group. Cancer Statistics, 2020: Report From National Cancer Registry Programme, India. JCO Glob Oncol 2020; 6: 1063-1075
    CrossrefPubMedGoogle Scholar
  • 8 Nougaret S, Horta M, Sala E. et al. Endometrial cancer MRI staging: updated guidelines of the European Society of Urogenital Radiology. Eur Radiol 2019; 29 (02) 792-805
    CrossrefPubMedGoogle Scholar
  • 9 Sala E, Rockall AG, Freeman SJ, Mitchell DG, Reinhold C. The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. Radiology 2013; 266 (03) 717-740
    CrossrefPubMedGoogle Scholar
  • 10 National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 1.2022. Accessed on February 20, 2022, at: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
  • 11 Vargas HA, Akin O, Zheng J. et al. The value of MR imaging when the site of uterine cancer origin is uncertain. Radiology 2011; 258 (03) 785-792
    CrossrefPubMedGoogle Scholar
  • 12 NCG Guidelines for endometrial cancer. Accessed on February 20, 2022, at: https://tmc.gov.in/ncg/docs/PDF/DraftGuidelines/Gynaec/fwdncgcaendometriumguidelines/NCG_Endometrial_Cancer_Management_Guidelines.pdf
  • 13 Colombo N, Creutzberg C, Amant F. et al; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (01) 16-41
    CrossrefPubMedGoogle Scholar
  • 14 Haldorsen IS, Salvesen HB. What is the best preoperative imaging for endometrial cancer?. Curr Oncol Rep 2016; 18 (04) 25
    CrossrefPubMedGoogle Scholar
  • 15 Hensley ML, Barrette BA, Baumann K. et al. Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas. Int J Gynecol Cancer 2014; 24 (9, Suppl 3) S61-S66
    CrossrefPubMedGoogle Scholar
  • 16 Jiang T, Huang L, Zhang S. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer. BMC Cancer 2015; 15: 396
    CrossrefPubMedGoogle Scholar
  • 17 Bignotti E, Ragnoli M, Zanotti L. et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer 2011; 104 (09) 1418-1425
    CrossrefPubMedGoogle Scholar
  • 18 Committee on Practice Bulletins-Gynecology, Society of Gynecologic Oncology. ACOG practice bulletin no. 147: Lynch syndrome. Obstet Gynecol 2014; 124 (05) 1042-1054
    CrossrefPubMedGoogle Scholar
  • 19 Arko D, Takac I. High frequency transvaginal ultrasonography in preoperative assessment of myometrial invasion in endometrial cancer. J Ultrasound Med 2000; 19 (09) 639-643
    CrossrefPubMedGoogle Scholar
  • 20 Savelli L, Ceccarini M, Ludovisi M. et al. Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging. Ultrasound Obstet Gynecol 2008; 31 (05) 560-566
    CrossrefPubMedGoogle Scholar
  • 21 Kim SH, Kim HD, Song YS, Kang SB, Lee HP. Detection of deep myometrial invasion in endometrial carcinoma: comparison of transvaginal ultrasound, CT, and MRI. J Comput Assist Tomogr 1995; 19 (05) 766-772
    CrossrefPubMedGoogle Scholar
  • 22 Lakhman Y, Katz SS, Goldman DA. et al. Diagnostic performance of computed tomography for preoperative staging of patients with non-endometrioid carcinomas of the uterine corpus. Ann Surg Oncol 2016; 23 (04) 1271-1278
    CrossrefPubMedGoogle Scholar
  • 23 Haldorsen IS, Salvesen HB. Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques. Clin Radiol 2012; 67 (01) 2-12
    CrossrefPubMedGoogle Scholar
  • 24 Freeman SJ, Aly AM, Kataoka MY, Addley HC, Reinhold C, Sala E. The revised FIGO staging system for uterine malignancies: implications for MR imaging. Radiographics 2012; 32 (06) 1805-1827
    CrossrefPubMedGoogle Scholar
  • 25 Manfredi R, Mirk P, Maresca G. et al. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology 2004; 231 (02) 372-378
    CrossrefPubMedGoogle Scholar
  • 26 Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol 2009; 19 (06) 1529-1536
    CrossrefPubMedGoogle Scholar
  • 27 Otero-García MM, Mesa-Álvarez A, Nikolic O. et al. Role of MRI in staging and follow-up of endometrial and cervical cancer: pitfalls and mimickers. Insights Imaging 2019; 10 (01) 19
    CrossrefPubMedGoogle Scholar
  • 28 Lucas R, Cunha TM. ESUR quick guide to female pelvis imaging 1.0. 2019: European Society of Urogenital Radiology. Accessed March 01, 2022, at: http://www.esur.org/fileadmin/content/2019/ESUR2019-ESURQuickGuidetoFemale_Pelvis_Imaging.pdf
  • 29 Anand R. ICRI guidelines for imaging protocols in women's imaging 2020. https://icri.iria.org.in/wpcontent/uploads/2022/03/ICRI Guidelines for Imaging Protocols in Women's Imaging.pdf. Accessed on 22.11.2022
    Google Scholar
  • 30 Nougaret S, Lakhman Y, Vargas HA. et al. From staging to prognostication: achievements and challenges of MR imaging in the assessment of endometrial cancer. Magn Reson Imaging Clin N Am 2017; 25 (03) 611-633
    CrossrefPubMedGoogle Scholar
  • 31 Vora Z, Manchanda S, Sharma R. et al. Normalized apparent diffusion coefficient: a novel paradigm for characterization of endometrial and subendometrial lesions. Br J Radiol 2021; 94 (1117): 20201069
    CrossrefPubMedGoogle Scholar
  • 32 Park SB, Moon MH, Sung CK, Oh S, Lee YH. Dynamic contrast-enhanced MR imaging of endometrial cancer: optimizing the imaging delay for tumour-myometrium contrast. Eur Radiol 2014; 24 (11) 2795-2799
    CrossrefPubMedGoogle Scholar
  • 33 Lalwani N, Dubinsky T, Javitt MC. et al; American College of Radiology. ACR Appropriateness criteria® pretreatment evaluation and follow-up of endometrial cancer. Ultrasound Q 2014; 30 (01) 21-28
    CrossrefPubMedGoogle Scholar
  • 34 Mahajan A, Sable NP, Popat PB. et al. Magnetic resonance imaging of gynecological malignancies: role in personalized management. Semin Ultrasound CT MR 2017; 38 (03) 231-268
    CrossrefPubMedGoogle Scholar
  • 35 Barral M, Placé V, Dautry R. et al. Magnetic resonance imaging features of uterine sarcoma and mimickers. Abdom Radiol (NY) 2017; 42 (06) 1762-1772
    CrossrefPubMedGoogle Scholar
  • 36 Reinhold C, Ueno Y, Akin EA. et al; Expert Panel on GYN and OB Imaging. ACR appropriateness criteria® pretreatment evaluation and follow-up of endometrial cancer. J Am Coll Radiol 2020; 17 (11S): S472-S486
    CrossrefPubMedGoogle Scholar
  • 37 Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol 2007; 62 (01) 28-34 , discussion 35–36
    CrossrefPubMedGoogle Scholar
  • 38 Salani R, Khanna N, Frimer M, Bristow RE, Chen LM. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017; 146 (01) 3-10
    CrossrefPubMedGoogle Scholar
  • 39 Elit L, Reade CJ. Recommendations for follow-up care for gynecologic cancer survivors. Obstet Gynecol 2015; 126 (06) 1207-1214
    CrossrefPubMedGoogle Scholar
  • 40 Concin N, Creutzberg CL, Vergote I. et al. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Arch 2021; 478 (02) 153-190
    CrossrefPubMedGoogle Scholar
  • 41 Asher R, Obermair A, Janda M, Gebski V. Disease-free and survival outcomes for total laparoscopic hysterectomy compared with total abdominal hysterectomy in early-stage endometrial carcinoma: a meta-analysis. Int J Gynecol Cancer 2018; 28 (03) 529-538
    CrossrefPubMedGoogle Scholar
  • 42 Li X, Cheng Y, Dong Y. et al. Development and validation of predictive model for lymph node metastasis in endometrial cancer: a SEER analysis. Ann Transl Med 2021; 9 (07) 538
    CrossrefPubMedGoogle Scholar
  • 43 Kim SR, van der Zanden C, Ikiz H, Kuzelijevic B, Havelock J, Kwon JS. Fertility-sparing management using progestin for young women with endometrial cancer from a population-based study. J Obstet Gynaecol Can 2018; 40 (03) 328-333
    CrossrefPubMedGoogle Scholar
  • 44 Wortman BG, Creutzberg CL, Putter H. et al; PORTEC Study Group. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 2018; 119 (09) 1067-1074
    CrossrefPubMedGoogle Scholar
  • 45 Nout RA, Smit VT, Putter H. et al; PORTEC Study Group. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375 (9717): 816-823
    CrossrefPubMedGoogle Scholar
  • 46 Jamieson A, Bosse T, McAlpine JN. The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer. Ther Adv Med Oncol 2021;13:17588359211035959
    Google Scholar